Cross-strain HIV therapeutic vaccine for all geographical regions
A series of chimeric immunogenic polypeptides developed based on the HIVconsv methodology, capable of inducing robust, effective and cross-strain immunity to HIV, is available and tested in clinical trials.
Applications: HIV therapeutic or prophylactic vaccine
| Features | Benefits |
|---|---|
| First-generation HIVconsvX conserved vaccines delivered by simian adenovirus ChAdV63 and poxvirus MVA showed high immunogenicity across 8 trials in UK, EU and Africa | Wealth of clinical data and knowledge in the development of HIV cross-strain vaccines; Successfully elicit protective potential of killer T cells targeting regions in HIVconsvX |
| Second-generation tHIVconsvX with conserved protein regions common to global variants delivered by simian adenovirus ChAdOx1 and poxvirus MVA are being tested in a heterologous prime-boost regimen | HIVconsvX vaccine with maximum HIV epitope match that protect against all HIV escape variants; ChAdOx1, a platform used in the Oxford/Astra-Zeneca vaccine for SARS-CoV2, a licensed and proven effective vaccine |
| Immunogen delivery applicable to other vaccine platforms e.g. RNA | Viable vaccine modalities for effective therapeutic or prophylactic use |
Patented and Available For
- Co-development
- Licensing